2 Corporate Drive
South San Francisco
About PACT Pharma
PACT Pharma is an exciting, well-funded clinical stage company developing personalized adoptive T cell therapies for the eradication of solid tumors. Our private designer T cells are created by analyzing a patient’s individual tumor and engineering T cells to kill that specific tumor. In principle, this technology can be used to treat any cancer type.
PACT is developing tumor-mutation targeted T Cells tailored for each patient. Tumor mutation neoepitope (neoE) targeting is programmed into the patient's own T cells to seek out & kill the tumors. Using (non-viral) precision genome engineering, the neoE-targeted T cell receptors (TCRs) replace the endogenous TCR of fresh CD8 and CD4 T cells collected from that same patient followed by minimal expansion in closed systems for re-infusion into the patient. These patient-specific neoTCR-P1 cells are formulated to immediately kill all neoantigen-expressing tumors, together with a deep reservoir of `ready-to-go' neoTCR-P1 cells for long term persistence and capable of rapid expansion to prevent future cancer recurrence.
If you desire a stimulating fast paced environment working with intelligent people who are making an impact in cancer, you will want to join the PACT Pharma team. We are a rapidly expanding, innovative, and collaborative team working towards one main goal: eradicating cancer!
We are in the San Francisco bay area, the heart of the world’s premier biotechnology research hub. PACT Pharma offers a competitive compensation and benefits package, including participation in the aggressive growth of the company in the form of stock option grants.
13 articles with PACT Pharma
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
PACT Pharma Highlights Capabilities and Versatility of Novel Non-Viral Gene Editing Technology in Presentation at American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
The poster presentation reported research findings by PACT scientists demonstrating the ability to utilize the company’s PACT^NV technology to generate TCR T cells in a single step.
PACT Reports New Data on First-of-its-Kind Personalized Neoantigen Platform for Adoptive T Cell Therapies at American Association for Cancer Research (AACR) Annual Meeting 2022
PACT Pharma, Inc. today announced that new data highlighting several aspects of its first-of-its-kind personalized neoantigen platform for adoptive cell therapies were presented in five separate poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022.
PACT Reports New Data Highlighting Predictive Power of Machine Learning Approach Leveraging PACTImmune™ Database at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, announced that new data related to its PACTImmune™ Database were presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting.
Scott Garland, the former chief executive officer of Portola Pharmaceuticals, will become the next CEO of South San Francisco-based PACT Pharma.
PACT Pharma, Inc., a clinical-stage company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors, today announced that the company will present at the 39 th Annual J.P. Morgan Healthcare Conference, which is being held virtually, on January 11, 2021 at 7:30 a.m. PT / 10:30 a.
- Under the partnership, PACT Pharma will provide the company with insight into autologous NeoTCR manufacturing workflows to help identify product-market fit and secure early access to the technology for an undisclosed amount - PACT Pharma is the second organization and first industry partner to join the program following Fred Hutchinson Cancer Research Center
--Companies will leverage their highly complementary technologies to address target specificity for tumor cells and cell exhaustion, two significant barriers for solid tumor T cell therapy--
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Mehra brings significant experience scaling organizations, an important skill as PACT grows and enters the clinic.
Moore led development of one of only two FDA-approved CAR-T therapies.
Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets
PACT's gene-edited T cells were observed to kill tumor cells by targeting patient-specific tumor mutation targets in non-clinical testing
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.